Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1984 11
1985 12
1986 8
1987 6
1988 3
1989 5
1990 4
1991 4
1992 7
1993 10
1994 18
1995 11
1996 8
1997 9
1998 12
1999 4
2000 6
2001 10
2002 17
2003 6
2004 6
2005 4
2006 7
2007 8
2008 8
2009 12
2010 13
2011 12
2012 16
2013 16
2014 13
2015 25
2016 24
2017 34
2018 29
2019 9
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

381 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA, et al. JAMA 2018 - Clinical Trial. PMID 30208454 Free PMC article.
Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum β-lactamase producers. OBJECTIVES: To determine whether definitive therapy with piperacillin-tazobactam is noninferior to meropenem (a carbapenem) in patients with bloodstream infection caused by ceftriaxone-nonsusceptible E coli or K pneumoniae. ...Effects were consistent in an analysis of the per-protocol population. Nonfatal serious adverse events occurred in 5 of 188 patients (2.7%) in the piperacillin-tazobactam group and 3 of 191 (1.6%) in the meropenem group. ...
Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum β-lactamase producers. OBJECTIVES:
Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis.
Luther MK, et al. Crit Care Med 2018 - Review. PMID 29088001
Effect estimates and 95% CIs were calculated using the random effects model in RevMan 5.3. DATA SYNTHESIS: Literature search identified 15 published studies and 17 conference abstracts with at least 24,799 patients. ...CONCLUSIONS: The combination of vancomycin plus piperacillin-tazobactam increased the odds of acute kidney injury over vancomycin monotherapy, vancomycin plus cefepime or carbapenem, and piperacillin-tazobactam monotherapy. ...
Effect estimates and 95% CIs were calculated using the random effects model in RevMan 5.3. DATA SYNTHESIS: Literature search identifi …
Hematologic Adverse Effects of Prolonged Piperacillin-Tazobactam Use in Adults.
Benli A, et al. Turk J Haematol 2018. PMID 29856362 Free PMC article.
OBJECTIVE: We aimed to find the incidence and risk factors of hematologic adverse effects of piperacillin-tazobactam (TZP). MATERIALS AND METHODS: Adult patients who used TZP for more than 10 days were included in the study. ...Patients with IHEC may be more prone to allergic reactions, so immunological mechanisms may facilitate the development of hematological adverse effects of TZP....
OBJECTIVE: We aimed to find the incidence and risk factors of hematologic adverse effects of piperacillin-tazobactam (T …
The Nephrotoxicity of Vancomycin
Filippone EJ, et al. Clin Pharmacol Ther 2017 - Review. PMID 28474732 Free PMC article.
Risk factors for nephrotoxicity are enumerated, including the potential synergistic nephrotoxicity of vancomycin and piperacillin-tazobactam. ...
Risk factors for nephrotoxicity are enumerated, including the potential synergistic nephrotoxicity of vancomycin and piperacillin-taz …
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS, et al. JAMA 2018 - Clinical Trial. PMID 29486041 Free PMC article.
OBJECTIVE: To evaluate efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infection (UTI), including acute pyelonephritis. ...Adverse events were reported in 106 of 272 (39.0%) with meropenem-vaborbactam vs 97 of 273 (35.5%) with piperacillin-tazobactam. ...
OBJECTIVE: To evaluate efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infection (UTI), including a …
Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
Mullins BP, et al. Ann Pharmacother 2018 - Clinical Trial. PMID 29442542
OBJECTIVES: To compare the incidence of nephrotoxicity in patients receiving intravenous vancomycin in combination with cefepime, meropenem, or piperacillin/tazobactam. METHODS: This was a prospective, multicenter observational study of patients receiving vancomycin in combination with piperacillin/tazobactam versus cefepime or meropenem. ...
OBJECTIVES: To compare the incidence of nephrotoxicity in patients receiving intravenous vancomycin in combination with cefepime, meropenem, …
Generalized fixed drug eruption to piperacillin/tazobactam and review of literature.
Kornmehl H, et al. Dermatol Online J 2018 - Review. PMID 29906010 Free article.
Fixed drug eruption (FDE) is an adverse drug reaction characterized by the development of well-circumscribed, round, dusky erythematous macules and plaques on cutaneous or mucosal surfaces. ...Herein, we present a 31year-old man with history of cystic fibrosis who developed a generalized fixed drug eruption to piperacillin/tazobactam (Zosyn, Pfizer). ...
Fixed drug eruption (FDE) is an adverse drug reaction characterized by the development of well-circumscribed, round, dusky erythemato …
Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?
Balcı C, et al. Int J Antimicrob Agents 2018. PMID 29649586
The combination of piperacillin/tazobactam (TZP) and vancomycin (VAN) provides a wide spectrum of activity against many pathogens acquired in healthcare settings. ...
The combination of piperacillin/tazobactam (TZP) and vancomycin (VAN) provides a wide spectrum of activity against many pathogens acq …
Piperacillin-Tazobactam-induced Adverse Drug Events in Pediatric Patients on Outpatient Parenteral Antimicrobial Therapy.
Yusef D, et al. Pediatr Infect Dis J 2017. PMID 27749652
We report a significantly higher occurrence of adverse events associated with prolonged courses of piperacillin-tazobactam compared with other antibacterial agents used for pediatric outpatient parenteral antimicrobial therapy. ...Adverse events related to piperacillin-tazobactam should be considered in patients who develop a febrile illness associated with a prolonged course of therapy....
We report a significantly higher occurrence of adverse events associated with prolonged courses of piperacillin-tazobactam com …
Bloodstream infections in neutropenic cancer patients: A practical update
Gustinetti G and Mikulska M. Virulence 2016 - Review. PMID 27002635 Free PMC article.
In these cases, the traditional choices such as oral therapy, ceftazidime, cefepime, piperacillin-tazobactam, or even carbapenems, might be ineffective. ...
In these cases, the traditional choices such as oral therapy, ceftazidime, cefepime, piperacillin-tazobactam, or even carbapenems, mi …
381 results
Jump to page
Feedback